{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:26:40Z","timestamp":1793698000059,"version":"4.5.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clml.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:25:33Z","timestamp":1786029933000},"page":"e1229-e1240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Observational Study of Patients With Chronic Lymphocytic Leukemia Treated With Fixed Duration Therapy in a 1L Setting in Canada"],"prefix":"10.1016","volume":"26","author":[{"given":"Carolyn","family":"Owen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariet Mathew","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2423-3629","authenticated-orcid":false,"given":"Mackenzie A.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1796-6918","authenticated-orcid":false,"given":"Simar","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.clml.2026.08.001_bib0001","doi-asserted-by":"crossref","first-page":"E615","DOI":"10.1503\/cmaj.240095","article-title":"Projected estimates of cancer in Canada in 2024","volume":"196","author":"Brenner","year":"2024","journal-title":"CMAJ"},{"key":"10.1016\/j.clml.2026.08.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107016","article-title":"Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update","volume":"125","author":"Owen","year":"2023","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.clml.2026.08.001_bib0003","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2026.08.001_bib0004","unstructured":"Cancer Care Alberta. Clinical practice Guideline LYHE-007: chronic lymphocytic leukemia. July 2025, Version 12."},{"issue":"21","key":"10.1016\/j.clml.2026.08.001_bib0005","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.clml.2026.08.001_bib0006","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus Ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.08.001_bib0007","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.08.001_bib0008","article-title":"Fixed-duration versus continuous treatment for chronic lymphocytic leukemia","author":"Al-Sawaf","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.08.001_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3324\/haematol.2013.096297","article-title":"Chronic lymphocytic leukemia in young individuals revisited","volume":"99","author":"Delgado","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.08.001_bib0010","unstructured":"AbbVie. AbbVie Receives Health Canada approval for the combination of VENCLEXTA\u00ae (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukemia. Available from: https:\/\/www.abbvie.ca\/content\/dam\/abbvie-dotcom\/ca\/en\/documents\/press-releases\/CLL14-Health-Canada-Approval-Press-Release-EN.pdf. Accessed January 15, 2026."},{"issue":"12","key":"10.1016\/j.clml.2026.08.001_bib0011","first-page":"1","article-title":"Reimbursement recommendation: venetoclax (Venclexta)","volume":"4","year":"2024","journal-title":"Can J Health Technol"},{"issue":"8","key":"10.1016\/j.clml.2026.08.001_bib0012","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/10428190600555819","article-title":"Sex differences in incidence and outcome of chronic lymphocytic leukemia patients","volume":"47","author":"Molica","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.08.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-184987","article-title":"Chronic lymphocytic leukemia (CLL) in adolescents and young adults (AYA): clinical characteristics, prognostic factors and survival for 498 patients","volume":"142","author":"Becerra","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.08.001_bib0014","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/hematology.2022000343","article-title":"Selecting initial therapy in CLL","volume":"2022","author":"Ahn","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"13","key":"10.1016\/j.clml.2026.08.001_bib0015","first-page":"13","article-title":"Chemoimmunotherapy in the first-line treatment of chronic lymphocytic leukaemia: dead yet, or alive and kicking?","author":"Smolej","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2026.08.001_bib0016","unstructured":"Targeted therapy for chronic lymphocytic leukemia. 2023 [cited 2025 Aug 24]; Available from: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/chronic-lymphocytic-leukemia-cll\/treatment\/targeted-therapy. Accessed January 15, 2026."},{"issue":"23","key":"10.1016\/j.clml.2026.08.001_bib0017","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.08.001_bib0018","series-title":"The Canadian Cancer Research Conference - November 2025","article-title":"The hidden burden: financial, physical, and psychosocial impacts of travel to treatment for Canadian blood cancer patients","author":"McMillan","year":"2025"},{"issue":"8","key":"10.1016\/j.clml.2026.08.001_bib0019","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2026.08.001_bib0020","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMra2300923","article-title":"Tumor lysis syndrome","volume":"393","author":"Bociek","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.08.001_bib0021","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1182\/blood-2024-200632","article-title":"CRISTALLO: results from a phase III trial of venetoclax-obinutuzumab versus fludarabine, cyclophosphamide and rituximab or bendamustine-rituximab in patients with untreated chronic lymphocytic leukemia without Del (17p) or TP53 mutations","volume":"144","author":"Sharman","year":"2024","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600251X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600251X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:35:11Z","timestamp":1793694911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502600251X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S215226502600251X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.08.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Observational Study of Patients With Chronic Lymphocytic Leukemia Treated With Fixed Duration Therapy in a 1L Setting in Canada","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}